1623P - Organization of nationwide EGFR testing in Russia: first experience

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Personalised/Precision Medicine
Basic Principles in the Management and Treatment (of cancer)
Presenter Evgeny Imyanitov
Citation Annals of Oncology (2014) 25 (suppl_4): iv546-iv563. 10.1093/annonc/mdu358
Authors E. Imyanitov1, I. Demidova2, T. Kikeeva3, M. Gordiev4, M.L. Filipenko5, Y. Molyaka6, V. Kozhemyako7, N.V. Cherdyntseva8, I. Tsimafeyeu9, S. Tjulandin10
  • 1Laboratory Of Molecular Oncology, N.N. Petrov Research Institute of Oncology, 197758 - St. Petersburg/RU
  • 2Laboratory Of Molecular Genetic, Moscow city oncology hospital #62, 143423 - Krasnogorsk/RU
  • 3Molecular Genetic, Research Centre of Medical Genetics, Moscow/RU
  • 4Laboratory Of Molecular Genetic, Cancer Center of the Republic of Tatarstan, Kazan/RU
  • 5Novisibirskaea Region, Institute of Chemical Biology and Basic Medicine, Siberian Division of the Russian Academy of Medical Sciences, 630011 - Novosibirsk/RU
  • 6Laboratory Of Molecular Genetic, Krasnodar Regional Cancer Center, Krasnodar/RU
  • 7Laboratory, Pacific Institute of Bioorganic Chemistry, 690022 - Vladivostok/RU
  • 8Laboratory Of Molecular Oncology And Immunology, Cancer Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, 634050 - Tomsk/RU
  • 9Moscow, Russian Society of Clinical Oncology, 145784 - Moscow/RU
  • 10Clinical Pharmacology And Chemotherapy, N.N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU



EGFR mutations are associated with pronounced sensitivity of lung carcinomas (LC) to EGFR inhibitors, therefore EGFR testing is now considered to be a mandatory part of metastatic LC management. Frequency of EGFR mutations demonstrates significant racial and geographic variations. This study was supported by the Russian Society of Clinical Oncology and aimed to assess distribution of EGFR mutations in a large sample of Russian LC patients with inoperable LC.


Diagnostic EGFR testing was carried out within years 2013-2014 in 9 laboratories spread across various regions of Russia. The laboratories were permitted to choose the methodology of EGFR mutation detection according to their preferences.


EGFR mutations were detected in 1043/4981 (20.9%) adenocarcinomas (AC), 13/396 (3.3%) squamous cell carcinomas and 2/75 (2.7%) large cell carcinomas. Frequency of EGFR mutations in AC exceeded similar estimates in other white populations, that may be attributed to higher proportion of non-smokers in Russian patients with AC. Noticeable occurrence of EGFR mutations in squamous LC may be explained either by regional specifics or inconsistencies in histological LC subtyping. EGFR mutation frequency was higher in patients aged 60 or older (605/2836, 21.3%) than in younger subjects (466/2744, 17.0%) (p=0.000037). Contrary to ALK-mutated LC, young onset LC with mutations showed the lowest estimates of EGFR mutation occurrence (21-30 years: 2/28 (7.1%); 31-40 years: 23/179 (12.8%).


Russian patients with lung adenocarcinomas have high frequency of EGFR mutations. Distribution of EGFR mutations is age-related, being lowest in young-onset and highest in late-onset LC.


All authors have declared no conflicts of interest.